Full-Time

Biostatistical Programming Senior Manager

Updated on 9/6/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Bachelor's, Master's

Category
Biology & Biotech (1)
Required Skills
Python
SAS
R

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A BA/BSc or higher degree in biostatistics, statistics, mathematics, computer science, or another related quantitative or scientific subject, with at least 8 years of statistical programming experience in a clinical development environment.
  • Strong technical, communication, and leadership skills.
  • Ability to lead and manage programmers to complete programming activities successfully and on time for one or multiple studies from end to end.
  • Experience developing a successful offshore statistical programming team.
  • Flexibility and willingness to work across different time zones.
  • Advanced analysis and reporting skills in SAS, including SAS/STAT, SAS Macro, SAS Graph, and SAS SQL.
  • Prior regulatory submission experience for drug approval.
  • Thorough understanding of and experience with data quality and compliance checks.
  • Experience in software development, including gathering user requirements, creating technical specifications, developing code, and creating and driving test plans.
  • Experience working effectively in globally dispersed teams with cross-cultural partners.
  • Prior staff-development leadership and project-management experience.
  • Excellent oral and written English communication skills.
  • Ability to perform complex statistical programming and related tasks effectively.
Responsibilities
  • Ensure successful execution and delivery of Global Statistical Programming milestone analysis deliverables and regulatory submission packages for assigned products or product groups supported by the offshore programming team.
  • Work with the Global Programming Lead to implement programming strategies, functional standards, and industry requirements globally for assigned products.
  • Plan and monitor project progress and address issues accordingly.
  • Provide Global Statistical Programming product-level input into resource plans and budgets.
  • Monitor and utilize assigned staff at the product level according to priorities.
  • Lead or participate in departmental process-improvement initiatives and cross-functional working groups.
  • Assist with study and system audits and inspections by internal and external bodies.
  • Develop, review, and implement policies, standard operating procedures, and other controlled documents affecting Global Statistical Programming globally.
  • Provide hands-on support to assigned product areas as required.
  • Provide coaching and mentoring to local programming staff.
  • Provide input into career-development plans for staff on assigned projects.
Desired Qualifications
  • An MSc or higher degree in statistics, biostatistics, mathematics, or another related quantitative or scientific subject.
  • Familiarity with open-source programming tools such as R and Python, automation platforms, and emerging technologies in statistical programming.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10%, and management raised full-year guidance again.
  • Repatha sales jumped 37% in Q2 2026 on stronger cardiology and primary-care demand.
  • Amgen approved IMDYLLTRA in Europe and opened a 2027 Hyderabad innovation center.

What critics are saying

  • FDA scrutiny threatens Tavneos withdrawal after the NEJM retraction and data-alteration probe.
  • Prolia sales fell 32% in Q2 2026 as biosimilar competition intensifies.
  • MariTide failure would leave Amgen dependent on aging brands and biosimilars after 2027.

What makes Amgen unique

  • Amgen sells multiple billion-dollar medicines, reducing dependence on any single franchise.
  • Repatha now shows hard cardiovascular mortality benefit, strengthening payer and physician adoption.
  • MariTide's monthly dosing targets a convenience gap versus weekly GLP-1 incumbents.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 1st, 2026
Amgen's Repatha hits $953M in Q2 sales, up 37% as Cramer calls it "biggest market of all time

Jim Cramer highlighted Amgen's cholesterol drug Repatha as a key driver behind the company's 31% year-to-date rally, calling it an overlooked catalyst by Wall Street. The injectable treatment, administered every two weeks, reduces death risk by 20% in patients at high risk for heart attack or stroke. Repatha generated $953 million in second-quarter sales, up 37% year-over-year. US new prescriptions surged over 50%, split evenly between cardiologist use and primary-care adoption for high-risk patients. Cramer noted the drug works against diabetes and high cholesterol, though insurance reimbursement has posed challenges. Amgen trades at a forward PE of 19, compared to Eli Lilly's 32, whilst outperforming Lilly's 10% gain this year. Repatha is one of six growth drivers representing nearly 70% of Amgen's product sales. The company raised full-year revenue guidance to $38.2-$39.4 billion.

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.

PR Newswire
Aug 12th, 2026
Amgen to open new science and innovation centre in Hyderabad's Genome Valley

Amgen announced plans to open a new Science and Innovation Center in Genome Valley, Hyderabad, expected to be operational in 2027. The facility will join Amgen's global Research and Development network of seven research laboratories, expanding the company's scientific capabilities. The center will bring together scientists and technologists across discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine. It will integrate experimental science with data and digital innovation to accelerate the discovery and development of medicines. "The new center in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities," said Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen. The facility will complement Amgen's existing technology and innovation site in Hyderabad.

Yahoo Finance
Aug 9th, 2026
Amgen fair value rises to $372 after Q2 beat sparks analyst target hikes to $450

Amgen's modeled fair value has risen from $352.23 to $371.93 per share following strong Q2 results and updated analyst targets. Several firms, including Scotiabank, TD Cowen, BMO Capital, and Oppenheimer, lifted price targets to around $450, citing earnings revisions and a diversified product portfolio. Bernstein noted a 6.8% revenue beat and 12.5% non-GAAP EPS beat in Q2, with raised full-year guidance driven by portfolio-wide execution. Strength came from products including Repatha, Tezspire, Uplizna, Evenity, and Imdelltra. However, Wells Fargo and Citi maintain cautious stances with Equal Weight and Neutral ratings, suggesting current performance may already be priced in. BofA kept its Underperform rating, describing 2026 as focused on execution ahead of key 2027 readouts.